Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC Meeting Abstract


Authors: Yu, H. A.; Oxnard, G. R.; Spira, A. I.; Horn, L.; Weiss, J.; Feng, Y.; West, H. J.; Giaccone, G.; Evans, T. L.; Kelly, R. J.; Fleege, T.; Poondru, S.; Jie, F.; Aoyama, K.; Foley, M. A.; Whitcomb, D.; Keating, A. T.; Krivoshik, A. P.
Abstract Title: Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC
Meeting Title: 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036901795
PROVIDER: wos
Notes: Meeting Abstract: 8083 -- Source: Wos